Previous systematic reviews have reported that statins reduce the risk of mortality, hospitalization, and levels of inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6) in COPD patients (10, 11). Here, CRP is linked to chronic obstructive pulmonary disease.